Sign In
Buy LNTH
$100.25
+3.95 (+4.10%)
At Close: Jun 03, 2026
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D.
08:30am, Thursday, 30'th Jan 2025
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
Why Lantheus Holdings Stock Got Thrashed on Tuesday
04:30am, Wednesday, 29'th Jan 2025
Radiopharmaceutical specialist Lantheus Holdings (LNTH -7.30%) had some news to report Tuesday morning, but the market didn't greet it warmly. Following its announcement of a fresh acquisition, invest
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities
Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease
Lantheus Holdings: Powerhouse Potential In 2025
07:43pm, Wednesday, 01'st Jan 2025
Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
08:00am, Monday, 30'th Dec 2024
SYDNEY, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
07:14am, Monday, 30'th Dec 2024
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the
Lantheus Holdings: A Growing Business With Dominant Market Share
02:01pm, Thursday, 12'th Dec 2024
Lantheus Holdings (LNTH) is a profitable company with strong products like PYLARIFY and DEFINITY, both showing double-digit growth and dominant market share. Management has demonstrated excellent exec
Why Lantheus Holdings Stock Won Big on Wednesday
06:54pm, Wednesday, 20'th Nov 2024
Why Lantheus Holdings Stock Won Big on Wednesday
Lantheus Announces Share Repurchase Program
01:00am, Wednesday, 20'th Nov 2024
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to
Lantheus to Present at the Jefferies London Healthcare Conference
08:30am, Wednesday, 13'th Nov 2024
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling cl
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
10:06am, Friday, 08'th Nov 2024
Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnost
Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
11:27am, Wednesday, 06'th Nov 2024
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob
